Skip to main content
. Author manuscript; available in PMC: 2013 Mar 12.
Published in final edited form as: Hypertens Res. 2012 Nov 15;36(3):262–269. doi: 10.1038/hr.2012.184

Figure 2.

Figure 2

Effects of olmesartan add-on therapy on the after-treatment/baseline (A/B) ratios of (a) hs-CRP, (b) urinary AGT, (c) urinary 8-OHdG and (d) urinary type IV collagen. Forty-six hypertensive patients with CKD were randomly assigned to the olmesartan add-on group (ARB +) or the non-ARB group (ARB −). Measurements were collected at baseline and after the 16-week treatment period. To compare the effects of anti-hypertensive treatment in each group, the values of the variables after the 16-week active treatment period were normalized to those of the respective variables at baseline and are expressed as A/B ratios. The values of the A/B ratios are expressed as the mean ± s.d.